Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: a pooled analysis of 4 prospective …
S Pant, LK Martin, S Geyer, L Wei… - American journal of …, 2016 - journals.lww.com
Purpose: Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …
Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and …
G Friberg, K Kasza, EE Vokes… - Journal of Clinical …, 2005 - ascopubs.org
3020 Background: Bevacizumab is a monoclonal Ab to the vascular endothelial growth
factor (VEGF). VEGF increases vessel permeability by stimulating endothelial nitric oxide …
factor (VEGF). VEGF increases vessel permeability by stimulating endothelial nitric oxide …
Hypertension as a surrogate marker for the activity of anti-VEGF agents
O Mir, S Ropert, J Alexandre… - Annals of …, 2009 - annalsofoncology.org
found that the occurrence of hypertension [grade‡ 3 according to the National Cancer
Institute—Common Toxicity Criteria (NCI-CTC)[13]] was associated with a higher response …
Institute—Common Toxicity Criteria (NCI-CTC)[13]] was associated with a higher response …
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of …
S Pant, LK Martin, S Geyer, L Wei, K Van Loon… - Cancer, 2014 - Wiley Online Library
BACKGROUND Phase 3 studies of bevacizumab in patients with advanced pancreatic
cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge, no …
cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge, no …
[HTML][HTML] VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and …
LK Martin, X Li, B Kleiber, EC Ellison, M Bloomston… - Annals of oncology, 2012 - Elsevier
Background We investigated the safety and efficacy of bevacizumab combined with
gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreas …
gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreas …
[HTML][HTML] Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer
K Iede, T Yamada, M Ueda, Y Tsuda, S Nakashima… - Medicine, 2022 - journals.lww.com
Although the antitumor effects of antihypertensive drugs for patients with advanced
pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous …
pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous …
Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients
E Tahover, B Uziely, A Salah, M Temper, T Peretz… - Medical Oncology, 2013 - Springer
Bevacizumab treatment is associated with an increased risk of hypertension (HTN), a
potential marker for effectiveness. We aimed to assess whether grades 2–3 HTN during …
potential marker for effectiveness. We aimed to assess whether grades 2–3 HTN during …
[HTML][HTML] Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
Anti-vascular endothelial growth factor (VEGF) therapeutics such as bevacizumab, which
are widely used in cancer treatment, commonly leads to hypertension. Moreover …
are widely used in cancer treatment, commonly leads to hypertension. Moreover …
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis
SP Gampenrieder, F Romeder, C MUß… - Anticancer …, 2014 - ar.iiarjournals.org
Background: Several phase-III studies have shown improvements in terms of progression-
free survival (PFS) with bevacizumab when added to chemotherapy in advanced breast …
free survival (PFS) with bevacizumab when added to chemotherapy in advanced breast …
Evaluation of hypertension as a marker of bevacizumab efficacy
R Ryanne Wu, PA Lindenberg, R Slack… - Journal of …, 2009 - Springer
Background Predictive factors for efficacy of vascular endothelial growth factor pathway-
targeted therapies have not been identified or confirmed. Hypertension has been observed …
targeted therapies have not been identified or confirmed. Hypertension has been observed …